Targeting ubiquitin-specific peptidase 22 in solid tumours: from ubiquitination to immunotherapy
As a deubiquitinating enzyme, the function of ubiquitin-specific peptidase 22 (USP22) in tumours has attracted increasing attention. However, the regulatory mechanism underlying USP22’s tumour biological processes has not yet been thoroughly elucidated. Moreover, considering the importance of USP22 in immune regulation and clinical treatment, targeting USP22 to prevent tumour biological processes and improve immunotherapy is worthy of attention. Given the significance of USP22 in immune cell function and tumour progression, clarifying the molecular regulatory network of USP22 in different types of tumours is necessary. In this review, we summarise how USP22 regulates tumour biology and analyse the key role of USP22 in immune regulation to provide new insights into novel therapeutic strategies.
Authors
- Zhe Li (ORCID: https://orcid.org/0000-0002-0809-9434)
- Jingyi Liu (ORCID: https://orcid.org/0000-0001-7123-0119)
- LL Wang
- Yuanxin Tang
Institutions
- Fourth Affiliated Hospital of China Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2026-03-13
- DOI
- https://doi.org/10.3389/fcell.2026.1792632
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00